These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 23143842)

  • 1. Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: a randomised controlled trial.
    Shulgina L; Cahn AP; Chilvers ER; Parfrey H; Clark AB; Wilson EC; Twentyman OP; Davison AG; Curtin JJ; Crawford MB; Wilson AM
    Thorax; 2013 Feb; 68(2):155-62. PubMed ID: 23143842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Efficacy and Mechanism Evaluation of Treating Idiopathic Pulmonary fibrosis with the Addition of Co-trimoxazole (EME-TIPAC): study protocol for a randomised controlled trial.
    Hammond M; Clark AB; Cahn AP; Chilvers ER; Fraser WD; Livermore DM; Maher TM; Parfrey H; Swart AM; Stirling S; Thickett D; Whyte M; Wilson A
    Trials; 2018 Feb; 19(1):89. PubMed ID: 29402332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Co-trimoxazole (Trimethoprim-Sulfamethoxazole) vs Placebo on Death, Lung Transplant, or Hospital Admission in Patients With Moderate and Severe Idiopathic Pulmonary Fibrosis: The EME-TIPAC Randomized Clinical Trial.
    Wilson AM; Clark AB; Cahn T; Chilvers ER; Fraser W; Hammond M; Livermore DM; Maher TM; Parfrey H; Swart AM; Stirling S; Thickett DR; Whyte M;
    JAMA; 2020 Dec; 324(22):2282-2291. PubMed ID: 33289822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: an economic evaluation alongside a randomised controlled trial.
    Wilson EC; Shulgina L; Cahn AP; Chilvers ER; Parfrey H; Clark AB; Twentyman OP; Wilson AM
    Pharmacoeconomics; 2014 Jan; 32(1):87-99. PubMed ID: 24307539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Antimicrobial Therapy on Respiratory Hospitalization or Death in Adults With Idiopathic Pulmonary Fibrosis: The CleanUP-IPF Randomized Clinical Trial.
    Martinez FJ; Yow E; Flaherty KR; Snyder LD; Durheim MT; Wisniewski SR; Sciurba FC; Raghu G; Brooks MM; Kim DY; Dilling DF; Criner GJ; Kim H; Belloli EA; Nambiar AM; Scholand MB; Anstrom KJ; Noth I;
    JAMA; 2021 May; 325(18):1841-1851. PubMed ID: 33974018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A double blind randomised placebo controlled pilot study of oral co-trimoxazole in advanced fibrotic lung disease.
    Varney VA; Parnell HM; Salisbury DT; Ratnatheepan S; Tayar RB
    Pulm Pharmacol Ther; 2008; 21(1):178-87. PubMed ID: 17500020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial.
    Raghu G; van den Blink B; Hamblin MJ; Brown AW; Golden JA; Ho LA; Wijsenbeek MS; Vasakova M; Pesci A; Antin-Ozerkis DE; Meyer KC; Kreuter M; Santin-Janin H; Mulder GJ; Bartholmai B; Gupta R; Richeldi L
    JAMA; 2018 Jun; 319(22):2299-2307. PubMed ID: 29800034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daily co-trimoxazole prophylaxis to prevent mortality in children with complicated severe acute malnutrition: a multicentre, double-blind, randomised placebo-controlled trial.
    Berkley JA; Ngari M; Thitiri J; Mwalekwa L; Timbwa M; Hamid F; Ali R; Shangala J; Mturi N; Jones KD; Alphan H; Mutai B; Bandika V; Hemed T; Awuondo K; Morpeth S; Kariuki S; Fegan G
    Lancet Glob Health; 2016 Jul; 4(7):e464-73. PubMed ID: 27265353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of additional antimicrobial therapy on the outcomes of patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis.
    Chen CY; Chen CH; Wang CY; Lai CC; Chao CM; Wei YF
    Respir Res; 2021 Sep; 22(1):243. PubMed ID: 34526011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Behr J; Bendstrup E; Crestani B; Günther A; Olschewski H; Sköld CM; Wells A; Wuyts W; Koschel D; Kreuter M; Wallaert B; Lin CY; Beck J; Albera C
    Lancet Respir Med; 2016 Jun; 4(6):445-53. PubMed ID: 27161257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
    Maher TM; Corte TJ; Fischer A; Kreuter M; Lederer DJ; Molina-Molina M; Axmann J; Kirchgaessler KU; Samara K; Gilberg F; Cottin V
    Lancet Respir Med; 2020 Feb; 8(2):147-157. PubMed ID: 31578169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial.
    Raghu G; Brown KK; Collard HR; Cottin V; Gibson KF; Kaner RJ; Lederer DJ; Martinez FJ; Noble PW; Song JW; Wells AU; Whelan TP; Wuyts W; Moreau E; Patterson SD; Smith V; Bayly S; Chien JW; Gong Q; Zhang JJ; O'Riordan TG
    Lancet Respir Med; 2017 Jan; 5(1):22-32. PubMed ID: 27939076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
    Feng H; Zhao Y; Li Z; Kang J
    Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
    Wells AU; Flaherty KR; Brown KK; Inoue Y; Devaraj A; Richeldi L; Moua T; Crestani B; Wuyts WA; Stowasser S; Quaresma M; Goeldner RG; Schlenker-Herceg R; Kolb M;
    Lancet Respir Med; 2020 May; 8(5):453-460. PubMed ID: 32145830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment.
    Nathan SD; Costabel U; Albera C; Behr J; Wuyts WA; Kirchgaessler KU; Stauffer JL; Morgenthien E; Chou W; Limb SL; Noble PW
    Respir Med; 2019 Jul; 153():44-51. PubMed ID: 31153107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial.
    Behr J; Nathan SD; Wuyts WA; Mogulkoc Bishop N; Bouros DE; Antoniou K; Guiot J; Kramer MR; Kirchgaessler KU; Bengus M; Gilberg F; Perjesi A; Harari S; Wells AU
    Lancet Respir Med; 2021 Jan; 9(1):85-95. PubMed ID: 32822614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Author's response: co-trimoxazole treatment in idiopathic pulmonary fibrosis.
    Shulgina L; Cahn AP; Chilvers ER; Parfrey H; Clark AB; Wilson EC; Twentyman OP; Davison AG; Curtin JJ; Crawford MB; Wilson AM
    Thorax; 2013 Sep; 68(9):884-5. PubMed ID: 23935173
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of Qizhukangxian granules on idiopathic pulmonary fibrosis: a randomized, double blind, placebo-controlled and multicenter clinical pilot trial.
    Guo S; Song Y; Feng J; Liu S; Li Y; Liu M; Wei L; Zhang X; Xie H; Sun Z
    J Tradit Chin Med; 2020 Aug; 40(4):674-682. PubMed ID: 32744035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab.
    Raghu G; Martinez FJ; Brown KK; Costabel U; Cottin V; Wells AU; Lancaster L; Gibson KF; Haddad T; Agarwal P; Mack M; Dasgupta B; Nnane IP; Flavin SK; Barnathan ES
    Eur Respir J; 2015 Dec; 46(6):1740-50. PubMed ID: 26493793
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.